1471-0528/asset/BJO_left.gif?v=1&s=0fb87361cdb6be25fdf05019eed6d47f5143f610)
1471-0528/asset/olbannerright.gif?v=1&s=3892ef16ff18d6834c302faf85268a49f5fc588f)
TREOSULFAN (DIHYDROXYBUSULPHAN) IN THE MANAGEMENT OF OVARIAN CARCINOMA
Article first published online: 23 AUG 2005
DOI: 10.1111/j.1471-0528.1977.tb12581.x
Issue
1471-0528/asset/cover.gif?v=1&s=b4e1d96c46e18c61210d584b63c13ee375cf562b "BJOG: An International Journal of Obstetrics & Gynaecology")
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 84, Issue 4, pages 300–303, April 1977
Additional Information
How to Cite
Fennelly, J. (1977), TREOSULFAN (DIHYDROXYBUSULPHAN) IN THE MANAGEMENT OF OVARIAN CARCINOMA. BJOG: An International Journal of Obstetrics & Gynaecology, 84: 300–303. doi: 10.1111/j.1471-0528.1977.tb12581.x
Publication History
- Issue published online: 23 AUG 2005
- Article first published online: 23 AUG 2005
- Abstract
- References
- Cited By
Summary
Of 36 patients with ovarian carcinoma treated with treosulfan (dihydroxybusulphan) 30·5 per cent had a complete response for a mean of 19·0 months and 33·3 per cent had a partial response. Treosulfan may have a role in the management of ascites associated with ovarian neoplasm.